Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, December 01, 2022
WuXi STA, a subsidiary of WuXi AppTec announced the partnership with Multiply Labs (based in San Francisco, CA, USA), a robotics company that has developed industry-leading automated manufacturing systems to produce individualized drugs.
read more
Thursday, November 21, 2019
Under the terms of this agreement, WuXi STA will become the preferred Contract Development and Manufacturing Organization (CDMO) partner of Impact Therapeutics.
read more
STA Pharmaceutical announces that its API R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection for two APIs from the FDA – with no Form 483s issued.
read more
WuXi STA, a subsidiary of WuXi AppTec, announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus.
read more
WuXi STA announced the opening of its large-scale oligonucleotide API manufacturing facility in Changzhou, China.
read more
STA Pharmaceutical has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.
read more
Tuesday, February 09, 2021
WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland.
read more
STA Pharmaceutical announced its partner, Ascletis has received approval from China Food and Drug Administration of its Category 1 new drug, Ganovo, to treat viral hepatitis C.
read more
Wednesday, March 06, 2019
STA Pharmaceutical, a subsidiary of WuXi AppTec, and Ark Biosciences announced a strategic partnership for CMC development and manufacturing.
read more
STA Pharmaceutical, a subsidiary of WuXi AppTec, and Dizal Pharmaceutical have announced a strategic partnership.
read more
Thursday, February 22, 2018
STA Pharmaceutical and Regulus Therapeutics have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.
read more
STA Pharmaceutical announced its Jinshan manufacturing facility in Shanghai, China has successfully passed an inspection by the EMA with no critical and no major findings.
read more
Wednesday, March 27, 2019
STA Pharmaceutical WuXi STA announces its new drug product manufacturing facility in Waigaoqiao Free Trade Zone of Shanghai has passed its first GMP inspection by the European MPA.
read more
Monday, December 09, 2019
WuXi Vaccines will invest 240 million USD and build a new vaccine manufacturing facility in Ireland.
read more
STA Pharmaceutical, a WuXi AppTec group company, has merged with WuXi AppTec’s Pharmaceutical Development Services division.
read more